RENO, Nev., Aug. 27, 2025 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the final opportunity to own a beautifully designed townhome at Hilltop by Toll Brothers in Reno, Nevada. Move-in ready homes with Designer Appointed Features are available in the community, presenting a rare opportunity for discerning shoppers to secure a new home on a quick timeline in this premier Reno location. The stunning three-story townhomes at Hilltop combine elevated design with low-maintenance living. With finished basements, covered patios, and covered decks that extend the living space outdoors, every detail has been thoughtfully crafted to complement the Northern Nevada lifestyle. All remaining homes include 3 bedrooms, 2 to 3 full baths, 2 half baths, and 2-car garages, ranging...

50-Lounge Global Rollout blending Luxury Hospitality with Secure Digital Monetization KUALA LUMPUR, Malaysia, Aug. 27, 2025 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”), today announced a strategic partnership with Reveillon Group Limited (“Reveillon Group”), a leading Food and Beverage (F&B) operator with substantial operations across Malaysia, to co-launch a global network of Real-World Asset (RWA) Lounges and a groundbreaking RWA NFT platform. The initiative integrates luxury hospitality, blockchain tokenization, and AI-powered creator tools to unlock new monetization streams in the rapidly expanding creator economy while bridging value between the digital and physical worlds. Under this partnership, VCI Global’s subsidiary Smart Bridge Technology Limited (“Smart Bridge”) will lead...

WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under U.S. GAAP accounting rules are not reflected on the Company’s balance sheet, yet represent substantial long-term value. Tevogen will provide detailed information and valuation of these assets in the coming days. Tevogen’s key assets include:Intellectual Property Portfolio – Three wholly owned, granted U.S. patents and twelve pending U.S. patents, including two in artificial intelligence.Drug Development Platforms – ExacTcell™: highly purified, target-specific CD8+ cytotoxic T lymphocytes (CTL).Artificial Intelligence Technology & Partnerships – Strategic collaborations with Microsoft and Databricks supporting:• PredicTcell™,...

EDMONTON, Alberta, Aug. 27, 2025 (GLOBE NEWSWIRE) — Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”) today announced the results of its August 25, 2025 annual general meeting of shareholders. The Company announces the following 4 directors have been re-elected to the Company’s Board of Directors: J. Mark Lievonen, C.M., FCPA, FCA, LLD Jeffrey Shon, J.D.Madi R. Madiyalakan, Ph.D.Bradley J. Glass, J.D. At the meeting, shareholders reappointed the Company’s auditors, Kingston Ross Pasnak, LLP. “I would like to thank all of our Board members for their service to the Company”, said Dr. Madi R. Madiyalakan, Chief Executive Officer of Quest. “I am confident that Quest’s Board of Directors will be able to help the Company execute its business strategy to add value to our shareholders.” Approximately 50,288,000 shares were voted...

CNH announces pricing of its offering of €500,000,000 3.875% notes due September 2035 Basildon, August 27, 2025 CNH Industrial N.V. (NYSE: CNH) (“CNH”) today announces the successful pricing of its offering of €500,000,000 in principal amount of 3.875% notes due September 3, 2035 (the “Notes”) with an issue price of 98.906% of the principal amount. The closing of the offering is currently expected on September 3, 2025. The notes will be issued by CNH under its Euro Medium Term Note Programme. CNH intends to use the net proceeds from the offering for its general corporate purposes including repayment of existing debt. Application will be made for the Notes to be admitted to trading on the Global Exchange Market of Euronext Dublin. NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO U.S. PERSONS MiFID II and UK MiFIR professionals/ECPs-only...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will begin immediately to ensure robust supply and rapid access of this season’s vaccine in pharmacies, hospitals, and clinics across the countryNEW YORK and MAINZ, GERMANY, AUGUST 27, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at...